Protalix BioTherapeutics ^Companies

Protalix BioTherapeutics is a biopharmaceutical company that specializes in the development and manufacturing of recombinant therapeutic proteins. They have revolutionized the industry through their ProCellEx® plant cell-based protein expression system. Their main goal is to develop and commercialize a pipeline of novel and biosimilar proteins that target genetic disorders and inflammatory diseases. Protalix's achievements include the approval of their first FDA-approved plant cell-based recombinant therapeutic protein, ELELYSO™, for the treatment of Gaucher disease. They have also partnered with Pfizer for the worldwide development and commercialization of ELELYSO.